- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biofrontera Inc (BFRI)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2600
1.4000
52 wk Range
0.5547
1.4000
Biofrontera (BFRI) Earnings Dates & Reports
Find detailed information about the financial performance of Biofrontera Inc, including the latest Biofrontera earnings report and upcoming earnings date. Review key figures such as the BFRI share price, BFRI EPS (earnings per share), and revenue compared against their previously forecasted numbers.
To view advanced BFRI earnings and revenue information, sign up for your very own InvestingPro account.
To view advanced BFRI earnings and revenue information, sign up for your very own InvestingPro account.
Latest Release
13/08/2026
EPS / Forecast
-0.05 / -0.14
Revenue / Forecast
12M / 10.5M
All numbers in USD
Biofrontera Inc Earnings Call Summary for Q2/2026
- Biofrontera Q2 2026 revenue hit $12.0M vs. $10.5M forecast, up 32.9% YoY; net loss $0.05/share beat est. $0.14 loss; shares surged 9.6% to $1.37.
- Gross margin expanded to 80% from 71% YoY on new cost structure; adjusted EBITDA loss narrowed to $0.2M from $5.1M; company called it strongest Q2 ever.
- FDA set Sept. 28, 2026 action date for Ameluz sBCC approval, first PDT for cancerous skin tumors; full launch expected Q1 2027 following Q4 2026 outreach.
- Company plans Q3 2026 filing for actinic keratosis label expansion with expected Q3 2027 approval; maintains full-year 2026 revenue guidance despite ITC ruling.
- Cash position of $4.7M raises liquidity concerns amid ongoing burn; CFO targets 2026 breakeven via revenue growth, $1M milestone payment, potential credit facility.
Last Updated: 13/08/2026, 16:10
Read Full TranscriptFAQ
What Is Biofrontera's Earnings Per Share (TTM)?
The Biofrontera EPS for trailing twelve months (TTM) is -1.0194.
When Is The Next Biofrontera (BFRI) Earnings Date?
Biofrontera will release its next earnings report on 18/11/2026, according to their financial calendar.
What Is Biofrontera’s Revenue Forecasts For Upcoming Quarters?
Biofrontera’s revenue forecast is 9.00M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.